Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
92.2(c) 92.06(c) 91.73(c) 92.92(c) 90.94(c) Last
1 722 948 1 749 759 1 884 921 2 243 096 2 702 713 Volume
+1.74% -0.15% -0.36% +1.30% -2.13% Change
More quotes
Estimated financial data (e)
Sales 2021 37 720 M 42 774 M 42 774 M
Net income 2021 6 139 M 6 962 M 6 962 M
Net Debt 2021 9 928 M 11 259 M 11 259 M
P/E ratio 2021 18,7x
Yield 2021 3,63%
Sales 2022 40 058 M 45 425 M 45 425 M
Net income 2022 7 395 M 8 386 M 8 386 M
Net Debt 2022 6 538 M 7 415 M 7 415 M
P/E ratio 2022 15,4x
Yield 2022 3,84%
Capitalization 114 B 129 B 129 B
EV / Sales 2021 3,29x
EV / Sales 2022 3,01x
Nbr of Employees 99 412
Free-Float 88,4%
More Financials
Company
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular,... 
Read more
Sector
Pharmaceuticals
Calendar
02/04 | 01:30amEarnings Release
More about the company
Ratings of Sanofi
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about SANOFI
01/20Exclusive-Polish drug maker Polpharma working on bid for Advent's Zentiva - sources
RE
01/19Regeneron Says FDA to Review Libtayo/Chemotherapy Combo in First-Line NSCLC Treatment
DJ
01/19Sanofi, Regeneron Say Dupixent Significantly Reduces Itching in Prurigo Nodularis Patie..
MT
01/19Sanofi-Regeneron's Dermatitis Drug Lowers Itch, Skin Lesions In Late-Stage Trial
MT
01/19Sanofi Announces Second Positive Phase 3 Dupixent® Trial Confirms Significant Improveme..
CI
01/17Factbox-GSK's consumer healthcare business coveted by Unilever
RE
01/15Factbox-GSK's consumer health business
RE
01/15GSK rejects 50-billion-pound Unilever offer for consumer assets
RE
01/14SANOFI : Déclaration des transactions sur actions propres
PU
01/13Sanofi India's Managing Director to Step Down in April
MT
01/13SANOFI : JP Morgan keeps its Buy rating
MD
01/12SANOFI : Exscientia and Sanofi establish strategic research collaboration to develop AI-dr..
PU
01/10Exscientia and Sanofi establish strategic research collaboration to develop AI-driven p..
AQ
01/10Evidation Extends Collaboration with Sanofi to Develop and Apply Real-World Evidence
CI
01/10Alembic Pharmaceuticals Gets US FDA Tentative Nod for Dronedarone Tablets
MT
More news
News in other languages on SANOFI
01/20Exclusif - Le fabricant polonais de médicaments Polpharma prépare une offre pour Zentiv..
01/19CAC40 : au contact des 7200Pts, le luxe en vedette
01/19CAC40 : dans le vert, les valeurs du luxe en soutien
01/19Sanofi et Regeneron affirment que le Dupixent réduit significativement les démangeaison..
01/19BOLSA DE MADRID : Una boda y cuatro funerales
More news
Analyst Recommendations on SANOFI
More recommendations
Stock Trading Strategies
SANOFI - 01/11
The comeback of an upward trend can be anticipated
BUY
More Stock Trading Analysis
Analysis
Exclusive-Polish drug maker Polpharma working on bid for Advent's Zentiva - sources
Stock Pick
 SANOFI
The road to reinvention
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | MarketScreener
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 90,94 €
Average target price 106,75 €
Spread / Average Target 17,4%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Director
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI4.90%132 264
JOHNSON & JOHNSON-3.40%435 037
ROCHE HOLDING AG-3.69%322 260
PFIZER, INC.-8.47%303 375
ABBVIE INC.-1.75%235 181
NOVO NORDISK A/S-13.40%220 833